ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial

N. Mounier, P. Brice, S. Bologna, J. Briere, I. Gaillard, M. Heczko, J. Gabarre, O. Casasnovas, J. Jaubert, P. Colin, A. Delmer, A. Devidas, E. Bachy, E. Nicolas-Virelizier, A. Aoudjhane, C. Humbrecht, M. Andre, P. Carde

Open source

DOI
10.1093/annonc/mdu189
Published
2014-08
Container
Annals of Oncology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/annonc/mdu189,
  title = {ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial},
  author = {N. Mounier and P. Brice and S. Bologna and J. Briere and I. Gaillard and M. Heczko and J. Gabarre and O. Casasnovas and J. Jaubert and P. Colin and A. Delmer and A. Devidas and E. Bachy and E. Nicolas-Virelizier and A. Aoudjhane and C. Humbrecht and M. Andre and P. Carde},
  year = {2014},
  journal = {Annals of Oncology},
  doi = {10.1093/annonc/mdu189},
  url = {https://doi.org/10.1093/annonc/mdu189}
}

RIS

TY  - JOUR
TI  - ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial
AU  - N. Mounier
AU  - P. Brice
AU  - S. Bologna
AU  - J. Briere
AU  - I. Gaillard
AU  - M. Heczko
AU  - J. Gabarre
AU  - O. Casasnovas
AU  - J. Jaubert
AU  - P. Colin
AU  - A. Delmer
AU  - A. Devidas
AU  - E. Bachy
AU  - E. Nicolas-Virelizier
AU  - A. Aoudjhane
AU  - C. Humbrecht
AU  - M. Andre
AU  - P. Carde
PY  - 2014
JO  - Annals of Oncology
DO  - 10.1093/annonc/mdu189
UR  - https://doi.org/10.1093/annonc/mdu189
ER  - 

APA

Mounier, N., Brice, P., Bologna, S., Briere, J., Gaillard, I., Heczko, M., Gabarre, J., Casasnovas, O., Jaubert, J., Colin, P., Delmer, A., Devidas, A., Bachy, E., Nicolas-Virelizier, E., Aoudjhane, A., Humbrecht, C., Andre, M., & Carde, P. (2014). ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of Oncology. https://doi.org/10.1093/annonc/mdu189

Source records